Estrategia seguida
Biotech All-Star Tracker
a 25 oct 2026
Son posiciones y rendimientos de clientes de la estrategia seguida. No demuestran las posiciones ni las ganancias personales.
| Valor | Asignación | Ganancia/pérdida no realizada |
|---|---|---|
| KODKodiak Sciences Inc Common Stock | 12,1 % | No divulgado |
| ONCBeOne Medicines Ltd. American Depositary Shares | 6,2 % | No divulgado |
| ROIVRoivant Sciences Ltd. Common Shares | 5,8 % | No divulgado |
Solo parte de la cartera es pública · 16 posiciones adicionales no publicadas (75,9 %)
El cálculo requiere coste y valoración fechada en la misma moneda. Es una ganancia o pérdida no realizada, sin dividendos ni ganancias realizadas. Los datos ausentes no se estiman.
Rentabilidad publicada de la cartera
a 23 oct 2026 · Inicio: 20 ago 2026
- Último mes
- +1,34 %
- Desde el inicio
- -11,05 %
Metodología de rentabilidad
The performance data presented reflects the aggregated results of actual client portfolios managed by the Registered Investment Adviser (RIA), based on the trading activity in the securities contained in the relevant portfolio over the specified period. If fewer than 10 clients are invested in the portfolio, the data represents the aggregate performance of all clients following this strategy. Performance figures are shown net of advisory fees, calculated using the applicable subscription fee and an assumed $50,000 account size. Because subscription fees are flat rather than asset-based, accounts smaller than $50,000 would experience a higher effective fee percentage and lower net performance, while larger accounts would experience a lower effective fee percentage. Actual investor outcomes can vary due to factors like brokerage support for fractional shares, account size, trade timing, fees, and taxes, and past performance should not be interpreted as a guarantee of future results or typical of all portfolios.